Anti-CD19 chimeric antigen receptor targeting of CD19 + acute myeloid leukemia

Anti-CD19 chimeric antigen receptor targeting of CD19 + acute myeloid leukemia

Aberrant expression of CD19 in acute myeloid leukemia (AML) is commonly associated with t(8;21)(q22;q22), although AML cases lacking this translocation occasionally express CD19. Mixed-phenotype acute leukemia also frequently expresses CD19. Chimeric antigen receptor (CAR) technology is a major brea...

Full description

Bibliographic Details
Main Authors:	Gina Ma, Yi Wang, Tahmeena Ahmed, Ann-Leslie Zaslav, Laura Hogan, Cecilia Avila, Masayuki Wada, Huda Salman
Format:	Article
Language:	English
Published:	Elsevier 2018-01-01
Series:	Leukemia Research Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2213048917300729

Similar Items

Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia
by: Carol O’Hear, et al.
Published: (2015-03-01)

A nontandem novel compound chimeric antigen receptor redirected to target CD20‐CD19 positive B‐cell acute leukemias and B‐cell lymphoma
by: Vincent M DeStefano, et al.
Published: (2024-07-01)

P520: POINT OF CARE CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH ABERRANT CD19 ANTIGEN EXPRESSION
by: Ivetta Danylesko, et al.
Published: (2023-08-01)

Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia
by: Justin C. Boucher, et al.
Published: (2023-12-01)

Chimeric antigen receptor T cells targeting CD312 as a therapy for acute myeloid leukemia
by: Danni Xie, et al.
Published: (2025-01-01)

Chimeric Antigen Receptor T Cells Targeting CD19 and Ibrutinib for Chronic Lymphocytic Leukemia
by: Julio Delgado, et al.
Published: (2019-04-01)

Deletion of CD38 enhances CD19 chimeric antigen receptor T cell function
by: Kimberly Veliz, et al.
Published: (2024-06-01)

Anti-CD19 chimeric antigen receptor T-cell therapy for B-cell acute lymphoid leukemia
by: Aaron P. Rapoport
Published: (2024-04-01)

Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia
by: Cheng Zhang, et al.
Published: (2022-06-01)

Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia
by: Runxia Gu, et al.
Published: (2020-09-01)

Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22
by: Haiying Qin, et al.
Published: (2018-12-01)

Performance of anti-CD19 chimeric antigen receptor T cells in genetically defined classes of chronic lymphocytic leukemia
by: Veronika Mancikova, et al.
Published: (2020-05-01)

Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia
by: Guoqing Wei, et al.
Published: (2017-04-01)

Pediatric T-cell prolymphocytic leukemia with an isolated 12(p13) deletion and aberrant CD117 expression
by: Bellone Michael, et al.
Published: (2012-04-01)

CD44‐targeted chimeric antigen receptor‐T eradicates acute myeloid leukaemic stem cells
by: Linah A. Shahoumi
Published: (2022-12-01)

Improved Activity against Acute Myeloid Leukemia with Chimeric Antigen Receptor (CAR)-NK-92 Cells Designed to Target CD123
by: Michael A. Morgan, et al.
Published: (2021-07-01)

The treatment of follicular lymphoma with CD19-directed chimeric antigen receptor T-cell therapy
by: Ryan Jacobs, et al.
Published: (2024-06-01)

CD19/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia
by: Na Yang, et al.
Published: (2024-03-01)

Targets for chimeric antigen receptor T-cell therapy of acute myeloid leukemia
by: Christopher Schorr, et al.
Published: (2022-12-01)

Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia
by: Mingxue Fan, et al.
Published: (2017-08-01)

Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design
by: Haiying Qin, et al.
Published: (2021-09-01)

Myeloid lineage switch following CD7-targeted chimeric antigen receptor T-cell therapy in relapsed/refractory T-cell acute lymphoblastic leukemia
by: Ibrahim Aldoss, et al.
Published: (2023-07-01)

Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia
by: Hanren Dai, et al.
Published: (2015-11-01)

Donor-derived CD19-targeted chimeric antigen receptor T cells in adult transplant recipients with relapsed/refractory acute lymphoblastic leukemia
by: Ibrahim Aldoss, et al.
Published: (2023-07-01)

Predictors and implications of renal injury after CD19 chimeric antigen receptor T-cell therapy
by: Alexander P. Boardman, et al.
Published: (2024-11-01)

Infections in hematologic malignancy patients treated by CD19 chimeric antigen receptor T‐cell therapy
by: Linghui Zhou, et al.
Published: (2022-06-01)

Case report: Hashimoto’s thyroiditis after CD19 chimeric antigen receptor T-cell therapy
by: Panpan Chen, et al.
Published: (2022-10-01)

Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies
by: Zhitao Ying, et al.
Published: (2021-02-01)

CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide
by: Mark Gurney, et al.
Published: (2020-12-01)

The CD28-Transmembrane Domain Mediates Chimeric Antigen Receptor Heterodimerization With CD28
by: Yannick D. Muller, et al.
Published: (2021-03-01)

Chimeric Antigen Receptor T Cell Therapy in Acute Myeloid Leukemia: Trials and Tribulations
by: Swati Garg, et al.
Published: (2023-11-01)

In Vitro and In Vivo Antitumor Effect of Anti-CD33 Chimeric Receptor-Expressing EBV-CTL against CD33+ Acute Myeloid Leukemia
by: A. Dutour, et al.
Published: (2012-01-01)

Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD‐19 chimeric antigen receptor T‐cell therapy
by: Francesco Paolo Tambaro, et al.
Published: (2020-09-01)

Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy
by: Joshua A. Hill, et al.
Published: (2019-11-01)

Enhanced Expression of Anti-CD19 Chimeric Antigen Receptor in piggyBac Transposon-Engineered T Cells
by: Daisuke Morita, et al.
Published: (2018-03-01)

Successful treatment of relapsed acute B-cell lymphoblastic leukemia with CD20/CD22 bispecific chimeric antigen receptor T-cell therapy
by: Zuyu Liang, et al.
Published: (2020-12-01)

Clonal evolution from B-cell acute lymphoblastic leukemia with <i>BCR::ABL1</i> multilineage involvement to acute myeloid leukemia after multiple anti-CD19 chimeric antigen receptor T-cell therapy
by: Mei-Jing Liu, et al.
Published: (2024-07-01)

Chimeric antigen receptor T-cell therapy for acute myeloid leukemia: how close to reality?
by: Katherine D. Cummins, et al.
Published: (2019-07-01)

Chimeric antigen receptor T-cell therapy in the treatment of acute myeloid leukemia: Possible challenges
by: Rahul Jagdishchandra Mittal, et al.
Published: (2021-01-01)

Chimeric antigen receptor (CAR) modified T Cells in acute myeloid leukemia: limitations and expectations
by: Beatriz Guijarro-Albaladejo, et al.
Published: (2024-04-01)